Impaired in vitro erythropoiesis following deletion of the scl (Tal1) +40 enhancer is largely compensated for in Vivo despite a significant reduction in expression

Molecular and Cellular Biology

Volumn 33, Issue 6, 2013, Pages 1254-1266

  Ferreira, Rita ^a   Spensberger, Dominik ^a   Silber, Yvonne ^a   Dimond, Andrew ^a   Li, Juan ^a   Green, Anthony R ^a   Göttgens, Berthold ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAP17 PROTEIN; MEMBRANE PROTEIN; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; EMBRYONIC STEM CELL; ENHANCER REGION; ERYTHROID CELL; ERYTHROPOIESIS; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN CELL; UPREGULATION;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BONE MARROW; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; EMBRYONIC STEM CELLS; ENHANCER ELEMENTS, GENETIC; ERYTHROID CELLS; ERYTHROPOIESIS; HEMATOPOIESIS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS; SPLEEN;

EID: 84874705284     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01525-12     Document Type: Article

References (59)

1. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. 1996. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell 86:47-57.
2. Robb L, Elwood NJ, Elefanty AG, Kontgen F, Li R, Barnett LD, Begley CG. 1996. The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse. EMBO J. 15:4123-4129.
3. Robb L, Lyons I, Li R, Hartley L, Kontgen F, Harvey RP, Metcalf D, Begley CG. 1995. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc. Natl. Acad. Sci. U. S. A. 92:7075-7079.
4. Shivdasani RA, Mayer EL, Orkin SH. 1995. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature 373: 432-434.
5. Visvader JE, Fujiwara Y, Orkin SH. 1998. Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. Genes Dev. 12:473-479.
6. Bradley CK, Takano EA, Hall MA, Gothert JR, Harvey AR, Begley CG, van Eekelen JA. 2006. The essential haematopoietic transcription factor Scl is also critical for neuronal development. Eur. J. Neurosci. 23:1677-1689.
7. Elefanty AG, Begley CG, Hartley L, Papaevangeliou B, Robb L. 1999. SCL expression in the mouse embryo detected with a targeted lacZ reporter gene demonstrates its localization to hematopoietic, vascular, and neural tissues. Blood 94:3754-3763.
8. van Eekelen JA, Bradley CK, Gothert JR, Robb L, Elefanty AG, Begley CG, Harvey AR. 2003. Expression pattern of the stem cell leukaemia gene in the CNS of the embryonic and adult mouse. Neuroscience 122:421-436.
9. Green AR, Lints T, Visvader J, Harvey R, Begley CG. 1992. SCL is coexpressed with GATA-1 in hemopoietic cells but is also expressed in developing brain. Oncogene 7:653-660.
10. Visvader J, Begley CG, Adams JM. 1991. Differential expression of the LYL, SCL and E2A helix-loop-helix genes within the hemopoietic system. Oncogene 6:187-194.
11. Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. 2009. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature 457:892-895.
12. Curtis DJ, Hall MA, Van Stekelenburg LJ, Robb L, Jane SM, Begley CG. 2004. SCL is required for normal function of short-term repopulating hematopoietic stem cells. Blood 103:3342-3348.
13. Hall MA, Curtis DJ, Metcalf D, Elefanty AG, Sourris K, Robb L, Gothert JR, Jane SM, Begley CG. 2003. The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12. Proc. Natl. Acad. Sci. U. S. A. 100:992-997.
14. Mikkola HK, Klintman J, Yang H, Hock H, Schlaeger TM, Fujiwara Y, Orkin SH. 2003. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature 421:547-551.
15. Salmon JM, Slater NJ, Hall MA, McCormack MP, Nutt SL, Jane SM, Curtis DJ. 2007. Aberrant mast-cell differentiation in mice lacking the stem-cell leukemia gene. Blood 110:3573-3581.
16. Hall MA, Slater NJ, Begley CG, Salmon JM, Van Stekelenburg LJ, McCormack MP, Jane SM, Curtis DJ. 2005. Functional but abnormal adult erythropoiesis in the absence of the stem cell leukemia gene. Mol. Cell. Biol. 25:6355-6362.
17. Delabesse E, Ogilvy S, Chapman MA, Piltz SG, Gottgens B, Green AR. 2005. Transcriptional regulation of the SCL locus: identification of an enhancer that targets the primitive erythroid lineage in vivo. Mol. Cell. Biol. 25:5215-5225.
18. Gottgens B, Ferreira R, Sanchez MJ, Ishibashi S, Li J, Spensberger D, Lefevre P, Ottersbach K, Chapman M, Kinston S, Knezevic K, Hoogenkamp M, Follows GA, Bonifer C, Amaya E, Green AR. 2010. cis-Regulatory remodeling of the SCL locus during vertebrate evolution. Mol. Cell. Biol. 30:5741-5751.
19. Kocher O, Cheresh P, Brown LF, Lee SW. 1995. Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique. Clin. Cancer Res. 1:1209-1215.
20. Jaeger C, Schaefer BM, Wallich R, Kramer MD. 2000. The membraneassociated protein pKe#192/MAP17 in human keratinocytes. J. Invest. Dermatol. 115:375-380.
21. Forsberg EC, Prohaska SS, Katzman S, Heffner GC, Stuart JM, Weissman IL. 2005. Differential expression of novel potential regulators in hematopoietic stem cells. PLoS Genet. 1:e28. doi:10.1371/journal.pgen .0010028.
22. Goh SH, Josleyn M, Lee YT, Danner RL, Gherman RB, Cam MC, Miller JL. 2007. The human reticulocyte transcriptome. Physiol. Genomics 30: 172-178.
23. Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, Castellvi J, Ruiz L, Ramon YCS, Carnero A. 2007. MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis 28:1646-1652.
24. Tijssen MR, Cvejic A, Joshi A, Hannah RL, Ferreira R, Forrai A, Bellissimo DC, Oram SH, Smethurst PA, Wilson NK, Wang X, Ottersbach K, Stemple DL, Green AR, Ouwehand WH, Gottgens B. 2011. Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev. Cell 2011:597-609.
25. Gottgens B, Broccardo C, Sanchez MJ, Deveaux S, Murphy G, Gothert JR, Kotsopoulou E, Kinston S, Delaney L, Piltz S, Barton LM, Knezevic K, Erber WN, Begley CG, Frampton J, Green AR. 2004. The scl +18/19 stem cell enhancer is not required for hematopoiesis: identification of a 5' bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1. Mol. Cell. Biol. 24:1870-1883.
26. Gottgens B, Nastos A, Kinston S, Piltz S, Delabesse EC, Stanley M, Sanchez MJ, Ciau-Uitz A, Patient R, Green AR. 2002. Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. EMBO J. 21:3039-3050.
27. Ogilvy S, Ferreira R, Piltz SG, Bowen JM, Gottgens B, Green AR. 2007. The SCL +40 enhancer targets the midbrain together with primitive and definitive hematopoiesis and is regulated by SCL and GATA proteins. Mol. Cell. Biol. 27:7206-7219.
28. Sinclair AM, Gottgens B, Barton LM, Stanley ML, Pardanaud L, Klaine M, Gering M, Bahn S, Sanchez M, Bench AJ, Fordham JL, Bockamp E, Green AR. 1999. Distinct 5' SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor binding sites. Dev. Biol. 209:128-142.
29. Silberstein L, Sanchez MJ, Socolovsky M, Liu Y, Hoffman G, Kinston S, Piltz S, Bowen M, Gambardella L, Green AR, Gottgens B. 2005. Transgenic analysis of the stem cell leukemia 19 stem cell enhancer in adult and embryonic hematopoietic and endothelial cells. Stem Cells 23:1378-1388.
30. Liu P, Jenkins NA, Copeland NG. 2003. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 13:476-484.
31. Su H, Mills AA, Wang X, Bradley A. 2002. A targeted X-linked CMV-Cre line. Genesis 32:187-188.
32. Wood AD, Chen E, Donaldson IJ, Hattangadi S, Burke KA, Dawson MA, Miranda-Saavedra D, Lodish HF, Green AR, Gottgens B. 2009. ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. Blood 114:1820-1830.
33. Kubo A, Shinozaki K, Shannon JM, Kouskoff V, Kennedy M, Woo S, Fehling HJ, Keller G. 2004. Development of definitive endoderm from embryonic stem cells in culture. Development 131:1651-1662.
34. Bockamp EO, Fordham JL, Gottgens B, Murrell AM, Sanchez MJ, Green AR. 1998. Transcriptional regulation of the stem cell leukemia gene by PU. 1 and Elf-1. J. Biol. Chem. 273:29032-29042.
35. Magnusson M, Brun AC, Lawrence HJ, Karlsson S. 2007. Hoxa9/hoxb3/ hoxb4 compound null mice display severe hematopoietic defects. Exp. Hematol. 35:1421-1428.
36. Spensberger D, Kotsopoulou E, Ferreira R, Broccardo C, Scott LM, Fourouclas N, Ottersbach K, Green AR, Gottgens B. 2012. Deletion of the Scl +19 enhancer increases the blood stem cell compartment without affecting the formation of mature blood lineages. Exp. Hematol. 40:588-598 e581.
37. Kassouf MT, Chagraoui H, Vyas P, Porcher C. 2008. Differential use of SCL/TAL-1 DNA-binding domain in developmental hematopoiesis. Blood 112:1056-1067.
38. Maetens M, Doumont G, Clercq SD, Francoz S, Froment P, Bellefroid E, Klingmuller U, Lozano G, Marine JC. 2007. Distinct roles of Mdm2 and Mdm4 in red cell production. Blood 109:2630-2633.
39. Chan WY, Follows GA, Lacaud G, Pimanda JE, Landry JR, Kinston S, Knezevic K, Piltz S, Donaldson IJ, Gambardella L, Sablitzky F, Green AR, Kouskoff V, Gottgens B. 2007. The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/-phenotype. Blood 109:1908-1916.
40. Aplan PD, Nakahara K, Orkin SH, Kirsch IR. 1992. The SCL gene product: a positive regulator of erythroid differentiation. EMBO J. 11: 4073-4081.
41. Barton LM, Gottgens B, Gering M, Gilbert JG, Grafham D, Rogers J, Bentley D, Patient R, Green AR. 2001. Regulation of the stem cell leukemia (SCL) gene: a tale of two fishes. Proc. Natl. Acad. Sci. U. S. A. 98:6747-6752.
42. Bockamp EO, McLaughlin F, Gottgens B, Murrell AM, Elefanty AG, Green AR. 1997. Distinct mechanisms direct SCL/tal-1 expression in erythroid cells and CD34 positive primitive myeloid cells. J. Biol. Chem. 272:8781-8790.
43. Bockamp EO, McLaughlin F, Murrell AM, Gottgens B, Robb L, Begley CG, Green AR. 1995. Lineage-restricted regulation of the murine SCL/ TAL-1 promoter. Blood 86:1502-1514.
44. Chapman MA, Donaldson IJ, Gilbert J, Grafham D, Rogers J, Green AR, Gottgens B. 2004. Analysis of multiple genomic sequence alignments: a web resource, online tools, and lessons learned from analysis of mammalian SCL loci. Genome Res. 14:313-318.
45. Gothert JR, Gustin SE, Hall MA, Green AR, Gottgens B, Izon DJ, Begley CG. 2005. In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood 105:2724-2732.
46. Gottgens B, Barton LM, Gilbert JG, Bench AJ, Sanchez MJ, Bahn S, Mistry S, Grafham D, McMurray A, Vaudin M, Amaya E, Bentley DR, Green AR, Sinclair AM. 2000. Analysis of vertebrate SCL loci identifies conserved enhancers. Nat. Biotechnol. 18:181-186.
47. Gottgens B, McLaughlin F, Bockamp EO, Fordham JL, Begley CG, Kosmopoulos K, Elefanty AG, Green AR. 1997. Transcription of the SCL gene in erythroid and CD34 positive primitive myeloid cells is controlled by a complex network of lineage-restricted chromatin-dependent and chromatin-independent regulatory elements. Oncogene 15:2419-2428.
48. Sanchez M, Gottgens B, Sinclair AM, Stanley M, Begley CG, Hunter S, Green AR. 1999. An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors. Development 126:3891-3904.
49. Chung YS, Zhang WJ, Arentson E, Kingsley PD, Palis J, Choi K. 2002. Lineage analysis of the hemangioblast as defined by FLK1 and SCL expression. Development 129:5511-5520.
50. Forsberg EC, Passegue E, Prohaska SS, Wagers AJ, Koeva M, Stuart JM, Weissman IL. 2010. Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. PLoS One 5:e8785. doi:10 .1371/journal.pone.0008785.
51. Minamishima YA, Kaelin WG, Jr. 2010. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 329:407.
52. Waskow C, Terszowski G, Costa C, Gassmann M, Rodewald HR. 2004. Rescue of lethal c-KitW/W mice by erythropoietin. Blood 104: 1688-1695.
53. Lacombe J, Herblot S, Rojas-Sutterlin S, Haman A, Barakat S, Iscove NN, Sauvageau G, Hoang T. 2010. Scl regulates the quiescence and the long-term competence of hematopoietic stem cells. Blood 115:792-803.
54. Barolo S. 2012. Shadow enhancers: frequently asked questions about distributed cis-regulatory information and enhancer redundancy. Bioessays 34:135-141.
55. Frankel N, Davis GK, Vargas D, Wang S, Payre F, Stern DL. 2010. Phenotypic robustness conferred by apparently redundant transcriptional enhancers. Nature 466:490-493.
56. Ahituv N, Zhu Y, Visel A, Holt A, Afzal V, Pennacchio LA, Rubin EM. 2007. Deletion of ultraconserved elements yields viable mice. PLoS Biol. 5:e234. doi:10.1371/journal.pbio.0050234.
57. Anguita E, Sharpe JA, Sloane-Stanley JA, Tufarelli C, Higgs DR, Wood WG. 2002. Deletion of the mouse alpha-globin regulatory element (HS-26) has an unexpectedly mild phenotype. Blood 100:3450-3456.
58. Bender MA, Byron R, Ragoczy T, Telling A, Bulger M, Groudine M. 2006. Flanking HS-62.5 and 3' HS1, and regions upstream of the LCR, are not required for beta-globin transcription. Blood 108:1395-1401.
59. Snow JW, Trowbridge JJ, Johnson KD, Fujiwara T, Emambokus NE, Grass JA, Orkin SH, Bresnick EH. 2011. Context-dependent function of "GATA switch" sites in vivo. Blood 117:4769-4772.